After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
The first data are dribbled out, but cross-trial comparisons look uninspiring.
Jazz’s Chimerix buy faces its big test.
More data from onvansertib's phase 2 study fail to convince.
NT-125 is discontinued, while two key Datroway readouts are delayed.
